<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36157581</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-0042</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>iScience</Title><ISOAbbreviation>iScience</ISOAbbreviation></Journal><ArticleTitle>Coxsackievirus B infections are common in Cystic Fibrosis and experimental evidence supports protection by vaccination.</ArticleTitle><Pagination><StartPage>105070</StartPage><MedlinePgn>105070</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">105070</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.isci.2022.105070</ELocationID><Abstract><AbstractText>Viral respiratory tract infections exacerbate airway disease and facilitate life-threatening bacterial colonization in cystic fibrosis (CF). Annual influenza vaccination is recommended and vaccines against other common respiratory viruses may further reduce pulmonary morbidity risk. Enteroviruses have been found in nasopharyngeal samples from CF patients experiencing pulmonary exacerbations. Using serology tests, we found that infections by a group of enteroviruses, Coxsackievirus Bs (CVBs), are prevalent in CF. We next showed that a CVB vaccine, currently undergoing clinical development, prevents infection and CVB-instigated lung damage in a murine model of CF. Finally, we demonstrate that individuals with CF have normal vaccine responses to a similar, commonly used enterovirus vaccine (inactivated poliovirus vaccine). Our study demonstrates that CVB infections are common in CF and provides experimental evidence indicating that CVB vaccines could be efficacious in the CF population. The role of CVB infections in contributing to pulmonary exacerbations in CF should be further studied.</AbstractText><CopyrightInformation>© 2022 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Virginia M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utorova</LastName><ForeName>Renata</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butrym</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sioofy-Khojine</LastName><ForeName>Amir-Babak</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hankaniemi</LastName><ForeName>Minna M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringqvist</LastName><ForeName>Emma E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanter</LastName><ForeName>Marfa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parajuli</LastName><ForeName>Anirudra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pincikova</LastName><ForeName>Terezia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stockholm CF Center, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Pediatrics, Karolinska University Hospital, 141 86 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischler</LastName><ForeName>Björn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Pediatrics, Karolinska University Hospital, 141 86 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karpati</LastName><ForeName>Ferenc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Stockholm CF Center, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Pediatrics, Karolinska University Hospital, 141 86 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hytönen</LastName><ForeName>Vesa P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, 33520 Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyöty</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, 33520 Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hjelte</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Stockholm CF Center, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Pediatrics, Karolinska University Hospital, 141 86 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flodström-Tullberg</LastName><ForeName>Malin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet and Karolinska University Hospital Huddinge, 141 52 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>iScience</MedlineTA><NlmUniqueID>101724038</NlmUniqueID><ISSNLinking>2589-0042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Virology</Keyword></KeywordList><CoiStatement>H.H. owns stocks in, and is the chairman of, the board of Vactech Ltd that develops vaccines against picornaviruses. H.H. and M.F.T. serve on the scientific advisory board of Provention Bio Inc. that develops vaccines against Coxsackie B viruses in collaboration with Vactech Ltd. The remaining authors declare that they have no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>26</Day><Hour>17</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36157581</ArticleId><ArticleId IdType="pmc">PMC9490033</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2022.105070</ArticleId><ArticleId IdType="pii">S2589-0042(22)01342-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Asner S., Waters V., Solomon M., Yau Y., Richardson S.E., Grasemann H., Gharabaghi F., Tran D. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J. Cyst. Fibros. 2012;11:433–439. doi: 10.1016/j.jcf.2012.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcf.2012.04.006</ArticleId><ArticleId IdType="pmc">PMC7105203</ArticleId><ArticleId IdType="pubmed">22579414</ArticleId></ArticleIdList></Reference><Reference><Citation>Browning M.J., Lim M.T.C., Kenia P., Whittle M., Doffinger R., Barcenas-Morales G., Kumararatne D., Viskaduraki M., O'Callaghan C., Gaillard E.A. Pneumococcal polysaccharide vaccine responses are impaired in a subgroup of children with cystic fibrosis. J. Cyst. Fibros. 2014;13:632–638. doi: 10.1016/j.jcf.2014.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcf.2014.02.002</ArticleId><ArticleId IdType="pubmed">24636807</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida M.B., Zerbinati R.M., Tateno A.F., Oliveira C.M., Romão R.M., Rodrigues J.C., Pannuti C.S., da Silva Filho L.V.F. Rhinovirus C and respiratory exacerbations in children with cystic fibrosis. Emerg. Infect. Dis. 2010;16:996–999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086221</ArticleId><ArticleId IdType="pubmed">20507756</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijkema J.S., van Ewijk B.E., Wilbrink B., Wolfs T.F.W., Kimpen J.L.L., van der Ent C.K. Frequency and duration of Rhinovirus infections in children with cystic fibrosis and healthy controls: a longitudinal cohort study. Pediatr. Infect. Dis. J. 2016;35:379–383. doi: 10.1097/INF.0000000000001014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000001014</ArticleId><ArticleId IdType="pubmed">26658528</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowaikh H., Morfin-Sherpa F., Reix P. Acute chest pain in an adolescent with cystic fibrosis in September: would you have thought about this? Pediatr. Pulmonol. 2017;52:E70–E72. doi: 10.1002/ppul.23746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.23746</ArticleId><ArticleId IdType="pubmed">28564496</ArticleId></ArticleIdList></Reference><Reference><Citation>Elborn J.S. Cystic fibrosis. Lancet. 2016;388:2519–2531. doi: 10.1016/s0140-6736(16)00576-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(16)00576-6</ArticleId><ArticleId IdType="pubmed">27140670</ArticleId></ArticleIdList></Reference><Reference><Citation>Etherington C., Naseer R., Conway S.P., Whitaker P., Denton M., Peckham D.G. The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation. J. Cyst. Fibros. 2014;13:49–55. doi: 10.1016/j.jcf.2013.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcf.2013.06.004</ArticleId><ArticleId IdType="pubmed">23891398</ArticleId></ArticleIdList></Reference><Reference><Citation>Eymery M., Morfin F., Doleans-Jordheim A., Perceval M., Ohlmann C., Mainguy C., Reix P. Viral respiratory tract infections in young children with cystic fibrosis: a prospective full-year seasonal study. Virol. J. 2019;16:111. doi: 10.1186/s12985-019-1208-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-019-1208-7</ArticleId><ArticleId IdType="pmc">PMC6724274</ArticleId><ArticleId IdType="pubmed">31481063</ArticleId></ArticleIdList></Reference><Reference><Citation>Flodstrom M., Horwitz M.S., Maday A., Balakrishna D., Rodriguez E., Sarvetnick N. A critical role for inducible nitric oxide synthase in host survival following coxsackievirus B4 infection. Virology. 2001;281:205–215. doi: 10.1006/viro.2000.0801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2000.0801</ArticleId><ArticleId IdType="pubmed">11277693</ArticleId></ArticleIdList></Reference><Reference><Citation>Garside J.P., Kerrin D.P., Brownlee K.G., Gooi H.C., Taylor J.M., Conway S.P. Immunoglobulin and IgG subclass levels in a regional pediatric cystic fibrosis clinic. Pediatr. Pulmonol. 2005;39:135–140. doi: 10.1002/ppul.20050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.20050</ArticleId><ArticleId IdType="pubmed">15633199</ArticleId></ArticleIdList></Reference><Reference><Citation>Garside J.P., Kerrin D.P., Brownlee K.G., Gooi H.C., Taylor J.M., Conway S.P. Low gammaglobulin subclass 2 levels in paediatric cystic fibrosis patients followed over a 2-year period. Pediatr. Pulmonol. 2007;42:125–130. doi: 10.1002/ppul.20473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.20473</ArticleId><ArticleId IdType="pubmed">17186508</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacalone V.D., Dobosh B.S., Gaggar A., Tirouvanziam R., Margaroli C. Immunomodulation in cystic fibrosis: why and how? Int. J. Mol. Sci. 2020;21:E3331. doi: 10.3390/ijms21093331.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093331</ArticleId><ArticleId IdType="pmc">PMC7247557</ArticleId><ArticleId IdType="pubmed">32397175</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson-Corley K.N., Olivier A.K., Meyerholz D.K. Principles for valid histopathologic scoring in research. Vet. Pathol. 2013;50:1007–1015. doi: 10.1177/0300985813485099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300985813485099</ArticleId><ArticleId IdType="pmc">PMC3795863</ArticleId><ArticleId IdType="pubmed">23558974</ArticleId></ArticleIdList></Reference><Reference><Citation>Goffard A., Lambert V., Salleron J., Herwegh S., Engelmann I., Pinel C., Pin I., Perrez T., Prévotat A., Dewilde A., Delhaes L. Virus and cystic fibrosis: rhinoviruses are associated with exacerbations in adult patients. J. Clin. Virol. 2014;60:147–153. doi: 10.1016/j.jcv.2014.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2014.02.005</ArticleId><ArticleId IdType="pmc">PMC7108260</ArticleId><ArticleId IdType="pubmed">24637203</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamalainen S., Nurminen N., Ahlfors H., Oikarinen S., Sioofy-Khojine A.B., Frisk G., Oberste M.S., Lahesmaa R., Pesu M., Hyöty H. Coxsackievirus B1 reveals strain specific differences in plasmacytoid dendritic cell mediated immunogenicity. J. Med. Virol. 2014;86:1412–1420. doi: 10.1002/jmv.23903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23903</ArticleId><ArticleId IdType="pubmed">24616040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamed D.H., Soliman M.S., Emam O.S., El-Attar M.M. Is there a role of viral infection in cystic fibrosis exacerbation in children? Turk. J. Pediatr. 2022;64:549–557. doi: 10.24953/turkjped.2020.1926.</Citation><ArticleIdList><ArticleId IdType="doi">10.24953/turkjped.2020.1926</ArticleId><ArticleId IdType="pubmed">35899568</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi M.M., Laitinen O.H., Stone V.M., Sioofy-Khojine A., Määttä J.A.E., Larsson P.G., Marjomäki V., Hyöty H., Flodström-Tullberg M., Hytönen V.P. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model. Vaccine. 2017;35:3718–3725. doi: 10.1016/j.vaccine.2017.05.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.05.057</ArticleId><ArticleId IdType="pubmed">28579231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi M.M., Stone V.M., Sioofy-Khojine A.B., Heinimäki S., Marjomäki V., Hyöty H., Blazevic V., Laitinen O.H., Flodström-Tullberg M., Hytönen V.P. A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine. Vaccine. 2019;37:5962–5971. doi: 10.1016/j.vaccine.2019.08.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.08.037</ArticleId><ArticleId IdType="pubmed">31471148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hostetler H.P., Neely M.L., Lydon E., Danziger-Isakov L.A., Todd J.L., Palmer S.M. Immunity to varicella, measles, and mumps in patients evaluated for lung transplantation. Am. J. Transplant. 2021;21:2864–2870. doi: 10.1111/ajt.16602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16602</ArticleId><ArticleId IdType="pubmed">33840158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyoty H., Leon F., Knip M. Developing a vaccine for type 1 diabetes by targeting coxsackievirus B. Expert Rev. Vaccines. 2018;17:1071–1083. doi: 10.1080/14760584.2018.1548281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1548281</ArticleId><ArticleId IdType="pubmed">30449209</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahn C.L., Felton O.L., Cherry J.D. Coxsackie B1 pneumonia in an adult. JAMA. 1964;189:236–237. doi: 10.1001/jama.1964.03070030058021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1964.03070030058021</ArticleId><ArticleId IdType="pubmed">14150011</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansen H.K., Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax. 1992;47:109–111. doi: 10.1136/thx.47.2.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.47.2.109</ArticleId><ArticleId IdType="pmc">PMC463585</ArticleId><ArticleId IdType="pubmed">1549817</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen O.H., Honkanen H., Pakkanen O., Oikarinen S., Hankaniemi M.M., Huhtala H., Ruokoranta T., Lecouturier V., André P., Harju R., et al. Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes. Diabetes. 2014;63:446–455. doi: 10.2337/db13-0619.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0619</ArticleId><ArticleId IdType="pubmed">23974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Lara-Reyna S., Holbrook J., Jarosz-Griffiths H.H., Peckham D., McDermott M.F. Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations. Cell. Mol. Life Sci. 2020;77:4485–4503. doi: 10.1007/s00018-020-03540-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-020-03540-9</ArticleId><ArticleId IdType="pmc">PMC7599191</ArticleId><ArticleId IdType="pubmed">32367193</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson P.G., Lakshmikanth T., Laitinen O.H., Utorova R., Jacobson S., Oikarinen M., Domsgen E., Koivunen M.R.L., Chaux P., Devard N., et al. A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models. Diabetologia. 2015;58:346–354. doi: 10.1007/s00125-014-3436-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-014-3436-0</ArticleId><ArticleId IdType="pubmed">25370797</ArticleId></ArticleIdList></Reference><Reference><Citation>Launay O., Boelle P.Y., Krivine A., Grenet D., Boussaud V., Rémus N., Corvol H., Chedevergne F., Hubert D., Sermet-Gaudelus I., Inserm MUCOFLU group Factors associated with humoral immune response to pandemic A/H1N1(v) 2009 influenza vaccine in cystic fibrosis. Vaccine. 2014;32:4515–4521. doi: 10.1016/j.vaccine.2014.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.06.010</ArticleId><ArticleId IdType="pubmed">24950362</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucidi V., Fiore L., Caniglia M., Rosati P., Novello F., Papadatou B., Medda E., Gentili G., Amato C., Castro M. Poliomyelitis and tetanus immunization: antibody responses in patients with cystic fibrosis. Pediatr. Infect. Dis. J. 1996;15:914–916. doi: 10.1097/00006454-199610000-00019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-199610000-00019</ArticleId><ArticleId IdType="pubmed">8895929</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjomaki V., Flodstrom-Tullberg M. Coxsackie B virus. Trends Microbiol. 2022;30:606–607. doi: 10.1016/j.tim.2022.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2022.01.016</ArticleId><ArticleId IdType="pubmed">35183399</ArticleId></ArticleIdList></Reference><Reference><Citation>Marson F.A.L., Bertuzzo C.S., Ribeiro J.D. Classification of CFTR mutation classes. Lancet Respir. Med. 2016;4:e37–e38. doi: 10.1016/s2213-2600(16)30188-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(16)30188-6</ArticleId><ArticleId IdType="pubmed">27377414</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews W.J., Williams M., Oliphint B., Geha R., Colten H.R. Hypogammaglobulinemia in patients with cystic fibrosis. N. Engl. J. Med. 1980;302:245–249. doi: 10.1056/nejm198001313020501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm198001313020501</ArticleId><ArticleId IdType="pubmed">7350477</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss R.B., Hsu Y.P., Van Eede P.H., Van Leeuwen A.M., Lewiston N.J., De Lange G. Altered antibody isotype in cystic fibrosis: impaired natural antibody response to polysaccharide antigens. Pediatr. Res. 1987;22:708–713. doi: 10.1203/00006450-198712000-00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/00006450-198712000-00020</ArticleId><ArticleId IdType="pubmed">3501565</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Ryan M., Bandyopadhyay A.S., Villena R., Espinoza M., Novoa J., Weldon W.C., Oberste M.S., Self S., Borate B.R., Asturias E.J., et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect. Dis. 2015;15:1273–1282. doi: 10.1016/S1473-3099(15)00219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00219-4</ArticleId><ArticleId IdType="pubmed">26318714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong E.L., Ellis M.E., Webb A.K., Neal K.R., Dodd M., Caul E.O., Burgess S. Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms. Thorax. 1989;44:739–742. doi: 10.1136/thx.44.9.739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.44.9.739</ArticleId><ArticleId IdType="pmc">PMC462055</ArticleId><ArticleId IdType="pubmed">2588211</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen N.T., Høiby N., Mordhorst C.H., Lind K., Flensborg E.W., Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa. Acta Paediatr. Scand. 1981;70:623–628. doi: 10.1111/j.1651-2227.1981.tb05757.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1651-2227.1981.tb05757.x</ArticleId><ArticleId IdType="pubmed">6798822</ArticleId></ArticleIdList></Reference><Reference><Citation>Provention Bio  . Provention Bio. 2021. Provention bio announces positive interim results from first-in-human study of coxsackievirus b vaccine candidate PRV-101.https://investors.proventionbio.com/2022-03-28-Provention-Bio-Announces-Positive-Final-Results-from-First-In-Human-Study-of-Coxsackievirus-B-Vaccine-Candidate-PRV-101</Citation></Reference><Reference><Citation>Richardson S.J., Morgan N.G. Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention. Curr. Opin. Pharmacol. 2018;43:11–19. doi: 10.1016/j.coph.2018.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2018.07.006</ArticleId><ArticleId IdType="pmc">PMC6294842</ArticleId><ArticleId IdType="pubmed">30064099</ArticleId></ArticleIdList></Reference><Reference><Citation>Semaniakou A., Croll R.P., Chappe V. Animal models in the pathophysiology of cystic fibrosis. Front. Pharmacol. 2018;9:1475. doi: 10.3389/fphar.2018.01475.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.01475</ArticleId><ArticleId IdType="pmc">PMC6328443</ArticleId><ArticleId IdType="pubmed">30662403</ArticleId></ArticleIdList></Reference><Reference><Citation>Singanayagam A., Joshi P.V., Mallia P., Johnston S.L. Viruses exacerbating chronic pulmonary disease: the role of immune modulation. BMC Med. 2012;10:27. doi: 10.1186/1741-7015-10-27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-10-27</ArticleId><ArticleId IdType="pmc">PMC3353868</ArticleId><ArticleId IdType="pubmed">22420941</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone V.M., Butrym M., Hankaniemi M.M., Sioofy-Khojine A.B., Hytönen V.P., Hyöty H., Flodström-Tullberg M. Coxsackievirus B vaccines prevent infection-accelerated diabetes in NOD mice and have No disease-inducing effect. Diabetes. 2021;70:2871–2878. doi: 10.2337/db21-0193.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db21-0193</ArticleId><ArticleId IdType="pmc">PMC8660981</ArticleId><ArticleId IdType="pubmed">34497136</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone V.M., Hankaniemi M.M., Laitinen O.H., Sioofy-Khojine A.B., Lin A., Diaz Lozano I.M., Mazur M.A., Marjomäki V., Loré K., Hyöty H., et al. A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci. Adv. 2020;6:eaaz2433. doi: 10.1126/sciadv.aaz2433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2433</ArticleId><ArticleId IdType="pmc">PMC7202868</ArticleId><ArticleId IdType="pubmed">32494709</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone V.M., Hankaniemi M.M., Svedin E., Sioofy-Khojine A., Oikarinen S., Hyöty H., Laitinen O.H., Hytönen V.P., Flodström-Tullberg M. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia. 2018;61:476–481. doi: 10.1007/s00125-017-4492-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4492-z</ArticleId><ArticleId IdType="pmc">PMC6448957</ArticleId><ArticleId IdType="pubmed">29151123</ArticleId></ArticleIdList></Reference><Reference><Citation>Svedin E., Utorova R., Hühn M.H., Larsson P.G., Stone V.M., Garimella M., Lind K., Hägglöf T., Pincikova T., Laitinen O.H., et al. A link between a common mutation in CFTR and impaired innate and adaptive viral defense. J. Infect. Dis. 2017;216:1308–1317. doi: 10.1093/infdis/jix474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix474</ArticleId><ArticleId IdType="pmc">PMC5853514</ArticleId><ArticleId IdType="pubmed">28968805</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doorninck J.H., French P.J., Verbeek E., Peters R.H., Morreau H., Bijman J., Scholte B.J. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J. 1995;14:4403–4411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394531</ArticleId><ArticleId IdType="pubmed">7556083</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ewijk B.E., van der Zalm M.M., Wolfs T.F.W., Fleer A., Kimpen J.L.L., Wilbrink B., van der Ent C.K. Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study. Pediatrics. 2008;122:1171–1176. doi: 10.1542/peds.2007-3139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2007-3139</ArticleId><ArticleId IdType="pubmed">19047230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Dong C., Chen D.E., Song Z. Visceral pathology of acute systemic injury in newborn mice on the onset of Coxsackie virus infection. Int. J. Clin. Exp. Pathol. 2014;7:890–904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3971291</ArticleId><ArticleId IdType="pubmed">24696708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wat D., Gelder C., Hibbitts S., Cafferty F., Bowler I., Pierrepoint M., Evans R., Doull I. The role of respiratory viruses in cystic fibrosis. J. Cyst. Fibros. 2008;7:320–328. doi: 10.1016/j.jcf.2007.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcf.2007.12.002</ArticleId><ArticleId IdType="pmc">PMC7105190</ArticleId><ArticleId IdType="pubmed">18255355</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>